Human CCL13/MCP-4 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB327
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
ELISA Capture (Matched Antibody Pair), Neutralization
Cited:
ELISA Development, Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 73506
Product Specifications
Immunogen
E. coli-derived recombinant human CCL13/MCP-4
Gln24-Thr98
Accession # Q99616.1
Gln24-Thr98
Accession # Q99616.1
Specificity
Detects human CCL13/MCP‑4 in ELISAs. In sandwich immunoassays, less than 1% cross-reactivity with recombinant human (rh) CCL2 is observed and no significant cross-reactivity or interference with rhCCL5,
7, 8, 11, 24, recombinant mouse CCL2, 5, 7, 11 or 12 is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CCL13/MCP-4 Antibody
Chemotaxis Induced by CCL13/MCP‑4 and Neutral-ization by Human CCL13/ MCP‑4 Antibody.
Recombinant Human CCL13/ MCP-4 (Catalog # 327-P4) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR2A in a dose dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL13/MCP-4 (2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL13/ MCP-4 Monoclonal Antibody (Catalog # MAB327). The ND50 is typically 10-30 µg/mL.Applications for Human CCL13/MCP-4 Antibody
Application
Recommended Usage
Neutralization
Measured by its ability to neutralize CCL13/MCP-4-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CCR2A. The Neutralization Dose (ND50) is typically 10-30 µg/mL in the presence of 2 µg/mL Recombinant Human CCL13/MCP-4.
Human CCL13/MCP-4 Sandwich Immunoassay
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL13/MCP-4
CCL13, also known as Monocyte Chemoattractant Protein-4 (MCP-4), is a CC chemokine that acts as a chemoattractant for monocytes, eosinophils and T cells and as an activator of basophils. Human CCL13 cDNA encodes a 98 amino acid residue precursor protein with a 23 amino acid residue hydrophobic signal peptide that is cleaved to yield an 8 kDa, 75 aa mature CCL13. Mature CCL13 lacks any potential N-glycosylation sites and shares a pyroglutamate proline motif with other human MCP proteins. Human CCL13 is most homologous to MCP-1, 3 and Eotaxin, exhibiting approximately 65-66% amino acid sequence identity. CCL13 mRNA is expressed by a number of activated cell types, including endothelial cells, macrophages, bronchial epithelium and type II alveolar cells, and perhaps lymphocytes. The bioactivities of CCL13 are mediated by the CC chemokine receptors CCR-2 and CCR-3.
Additional CCL13/MCP-4 Products
Product Documents for Human CCL13/MCP-4 Antibody
Product Specific Notices for Human CCL13/MCP-4 Antibody
For research use only
Loading...
Loading...
Loading...